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Mortality in Patients with Hemophilia
Changes in a Dutch Population from 1986 to 1992 and 1973 to 1986
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• Objective: To determine causes of death and mor-
tality rates in patients with hemophilia over a period of
20 years, to assess changes in mortality, and to distin-
guish between hemophilia-related death and recent
death induced by viral infections.
• Design: Cohort study of 919 patients followed from
January 1986 to June 1992. Results were compared
with outcomes of previous follow-up from 1973 to 1986.
• Setting: Consecutive national questionnaire surveys
on hemophilia, using patient registries of the Nether-
lands Hemophilia Society and Dutch hemophilia cen-
ters.
• Patients: 919 males with hemophilia A or B who
participated in a national questionnaire survey on he-
mophilia in 1985. Mediän duration of follow-up was 6.4
years, which yielded 5753 person-years of follow-up.
The mean age at study entry was 30 years (ränge, 1 to
85 years).
• Measurements: Standardized mortality ratios,
causes of death, median life expectancy, age-adjusted
relative risks associated with the type or severity of
hemophilia, presence of Inhibitors, prophylaxis, and
human immunodeficiency virus infection.
• Results: 45 patients (5%) died between January 1986
and June 1992; 22.6 patients had been expected to die.
Thus, the overall standardized mortality ratio was 2.0.
The overall median life expectancy was 66 years for the
cohort studied from 1973 to 1986 and 68 years for the
cohort studied from 1986 to 1992. When deaths related
to viral infection were excluded, the life expectancy
almost equaled that of the general male population.
Between 1986 and 1992, 1 patient died of ischemic
heart disease compared with the 5.2 who were ex-
pected to die of this disease. Infection with HIV was the
strongest independent predictor of death (relative risk,
27.5 [95% Cl, 5.7 to 132.8]). After adjustment for HIV
infection, no other hemophilia-related risk factors were
associated with the risk for death.
• Conclusions: The acquired immunodeficiency syn-
drome and hepatitis strongly influence mortality in
patients with hemophilia. In the absence of viral infec-
tions, the life expectancy of patients with hemophilia
would almost equal that of the general male population.
Ann Intern Med. 1995;123:823-827.
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JDefore 1960, hemophilia was characterized by excess
mortality caused by hemorrhages, mainly intracranial (l,
2). Substitution therapy, introduced in the 1960s, has con-
tributed to a decrease in hemophilia-related mortality (3-
8). However, survival decreased sharply in the 1980s be-
cause of deaths from human immunodeficiency virus
(HIV) infection or hepatitis, particularly in patients with
severe hemophilia (5, 7). The acquired immunodeficiency
syndrome (AIDS) caused an increase in mortality rates at
relatively young ages. Chorba and colleagues (7) reported
that for the years 1987 to 1989, AIDS had become the
predominant cause of death (55.1%) among patients with
hemophilia A in the United States; in addition, compared
with the period from 1979 to 1981, the number of deaths
from liver disease had increased more than threefold.
Patients with hemophilia who died of HlV-related dis-
eases between 1987 and 1989 had a median age of 34
years, whereas those who died of other causes had a
median age of 56 years (7).
The effect of HIV infections on mortality in patients
with hemophilia is obviously related to the percentage of
infected patients. Among Dutch hemophiliacs, the overall
percentage of those infected with HIV is approximately
13% (9), a relatively small percentage compared with that
in other European countries or the United States (10).
We describe our experiences with a cohort of 919 pa-
tients with hemophilia who were followed from 1986 to
1992. This report, together with a previous report (11) on
the results of a follow-up period from January 1973 to
January 1986 (n = 717), form a complete inventory of
mortality among Dutch hemophiliacs over 20 years. We
studied the manner in which virus-related deaths influ-
ence the survival of Dutch patients with hemophilia.
Methods
We selected a cohort of 919 patients who had hemophilia A or
B from 935 respondents to a questionnaire survey in 1985. The
total number of respondents represented about 75% of all Dutch
patients with hemophilia (12). The following respondents did not
meet the inclusion criteria for follow-up: 5 female carriers, 3
respondents who had other bleeding disorders, 7 anonymous
respondents to the 1985 survey, and l temporary foreign resi-
dent. The 919 remaining patients were followed from l January
1986 (ciosing date of the 1985 survey) to l June 1992. Five
patients emigrated during follow-up, and the end dates of 33
patients were censored before the end-of-study date because the
patients' addresses were no longer known. We used information
from municipal registries, physicians, and the Hemophilia Society
to assess the end dates of these patients.
We obtained information on date of birth, year of death, and
vital Status at the end-of-study date from the responses to the
latest survey, the attending physicians, or municipal population
registries. We obtained causes of death from physicians and
categorized them according to the ninth revision of the Interna-
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Table 1. General Characteristics of 919 Patients Followed
from 1986 to 1992
Severity of
Hemophilia
Severe*
Moderately severef
Μίΐαφ
Total
Patients
with
Hemophilia
A
n('
315 (40)
152 (19)
329 (41)
796
Patients
with
Hemophilia
B
7θ)
66 (54)
20 (16)
37 (30)
123
Mean Age
at Study
Entry
y
27
29
33
30
* Clotting factor level, <0.01 lU/mL.
t Clotting factor level, 0.01 to 0.05 lU/mL.
t Clotting factor level, 0.05 to 0.40 lU/mL.
tional Classification of Diseases, Injuries, and Causes of Death
(ICD-9) (13). This categorization permitted analyses of cause-
speciflc mortality. Hemorrhages were deflned äs the cause of
death only if no underlying fatal disorder was present. Data on
the severity of hemophilia, the presence of neutralizing antibod-
ies to factor VIII or IX (Inhibitors), the use of prophylactic
treatment, and the HIV lest result were derived from the self-
reported answers to the 1985 questionnaire. The severity of
hemophilia, depending on the residual clotting factor activity,
was categorized äs severe (clotting factor level < 0.01 lU/mL or
< 1% of the normal activity), moderately severe (clotting factor
level, 0.01 to 0.05 lU/mL), or mild (clotting factor level, 0.05 to
0.40 lU/mL).
To estimate the relative risk for overall and cause-specific
death, we used the patient-year method and calculated standard-
ized mortality ratios (expressed äs the ratio of the observed
number of deaths to the number that would be expected if the
mortality rates in the study cohort were the same äs those in the
general population, adjusted for sex and age). We used mortality
rates for the general male population in 1990 to calculate stan-
dardized mortality ratios for the study population followed from
1986 to 1992. The 95% CIs were based on the Poisson distribu-
tion.
We extrapolated the median life expectancy at l year of age
from life tables for the general male population in 1991. The
population mortality rates in each age interval were multiplied by
the overall relative mortality rate under the assumption that the
relative mortality over age was equal for all ages. The median life
expectancy is the age at which 50% of a hypothetical cohort of
1-year-old males will have died.
Finally, we simultaneously examined the contribution of sev-
eral factors to the risk for death in a multivariate survival model
(the Cox proportional hazards model) (14). The factors studied
were the type and severity of hemophilia, HIV Status, presence
of an inhibitor, and prophylactic treatment; age was entered into
the model äs an adjustment variable (in 18 categories, with
dummy variables). This model yielded the rate ratios (relative
risk) for each factor compared with the reference category of
that factor and adjusted for all other factors in the model.
Results
The cohort followed from 1986 to 1992 consisted of 919
patients, 796 with hemophilia A and 123 with hemophilia
B (Table 1). The mean age at study entry in 1986 was
29.6 years (ränge, 0.7 to 85.3 years). Patients with mild
hemophilia were, on average, older when they entered the
study than patients with moderately severe or severe he-
mophilia (33, 29, and 27 years, respectively).
With a median follow-up of 6.4 years, the 919 patients
contributed 5753 person-years of follow-up. Forty-five pa-
tients died between 1986 and 1992; 22.6 deaths had been
expected (that is, 22.6 deaths would have occurred in a
hypothetical cohort of the general male population with
an equal age distribution). The standardized mortality
ratio was 2.0 (CI, 1.5 to 2.7), indicating that the overall
mortality for patients with hemophilia was twice äs high
äs that in the general male population. For patients with
severe hemophilia, the mortality rate was four times
higher than expected (standardized mortality ratio, 4.0
[CI, 2.4 to 6.3]), whereas almost no excess in mortality
was seen for patients with mild hemophilia (standardized
mortality ratio, 1.1 [CI, 0.6 to 1.8]).
The median life expectancy at l year of age for mildly
affected patients with hemophilia was similar to that of
the general Dutch male population in 1991 (74 years).
Severely affected patients with hemophilia had the lowest
median life expectancy (61 years) (Table 2).
Cause-Specific Mortality
Causes of death are listed in Table 3. In the cohort
followed from 1986 to 1992, 12 patients died of AIDS (10
with severe hemophilia, l with moderately severe hemo-
philia, and l with mild hemophilia), and 5 died of liver
disease (3 with severe hemophilia, of whom l was HIV
positive; l with moderately severe hemophilia; and l with
mild hemophilia). The acquired immunodeficiency syn-
drome was the main cause of death between 1986 and
1992 (27%). Between 1973 and 1986, many deaths (35%)
were caused by malignant neoplasms. Of the 88 patients
who died in the 20 years spanned by both studies, 30 died
of defmite or probable bleeding (the latter including un-
specified strokes and trauma).
In the cohort studied from 1986 to 1992, the mean age
at death was 54 years (ränge, 16 to 91 years; median, 53
years). The average age of the patients who died of AIDS
Table 2. Mortality Data (1986 to 1992) and Life Expectancies by Severity and Type of Hemophilia
Variable
Severe hemophilia
Moderate hemophilia
Mild hemophilia
Total
Hemophilia A
Hemophilia B
Patients
381
172
366
919
796
123
Patient- Years
2396
1070
2287
5753
4984
769
Observed
Deaths
19
11
15
45
33
12
Standardized Mortality
Ratio (95% CI)*
4.0 (2.4 to 6.3)
2.6 (1.3 to 4.6)
1.1 (0.6 to 1.8)
2.0 (1.5 to 2.7)
1.8 (1.3 to 2.5)
2.8 (1.4 to 4.8)
Median Life
Expectancyf
y
61
65
74
68
69
64
* The standardized mortality ratio is the ratio of the observed number of deaths to the expected number, based on life-tables from 1990 for the general
male population.
t Calculated with life-tables from 1991 (median life expectancy of Dutch males, 74 years).
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Table 3. Causes of Death for the Periods 1973 to 1986 and 1986 to 1992*
Variable (ICD 9 Code) 1973 to 1986t 1986 to 1992Φ
AIDS (042-044, 136 279, 798)
Neoplasms
Mahgnant neoplasms (140 208)
Pseudotumor (229)
Ischemic heart disease
Myocardial mfarction (410)
Heart failure (411)
Cerebrovascular disease and hemorrhages§
Intracramal (431)
Digestive tract (578)
Other hemorrhages (459, 596, 599, 719)
Chromc hver disease and cirrhosis (571)
Injury and poisoning
Trauma or violence (E800 999)
Suicide (E950 959)
Other
Unknown
Total number of deaths
0(0)
15 (35)
0(0)
1(2)
0(0)
3(7)
1(2)
5(12)
0(0)
6(14)
2(5)
7(16)**
3(7)
43
12 (27)
6(13)
1(2)
0(0)
1(2)
9 (20)||
1(2)
0(0)
5 (11)11
2(4)
2(4)
2 (4)tt
4(9)
45
* AIDS = acquired immunodeficiency syndrome ICD 9 = International Classification of Diseases 9th Revision
1 7788 person years of follow up
φ 5753 person years of follow up
§ Hemorrhages counted only if no lethal underlymg cause was present
|| One person had AIDS
H One person had alcoholic hver cirrhosis
** Stroke (n — 3) renal failure (n — 3) and allergic reaction (n = 1)
tt Amyotrophic lateral sclerosis (n — 1) and old age (n = l aged 85 years)
was 46 years (ränge, 25 to 65 years, median, 47 years),
which was 11 years less than the average of 57 years
(ränge, 16 to 91 years, median, 62 years) for the 33
patients who died of other causes The mean age at death
of the 5 patients who died of hver disease was 50 years
(ränge, 35 to 64 years, median, 49 years)
The overall mortahty in both cohorts was approximately
twice that in the general male population (Table 4), and
the overall median life expectancy mcreased from 66
years durmg 1973 to 1986 to 68 years durmg 1986 to
1992 We recalculated the mortality ratlos after first ex-
cludmg all AIDS-related deaths and then all virus (HIV,
hepatitis)-related deaths This recalculation allowed us to
obtain hypothetical mortahty ratlos m the absence of
these mfections The exclusion of AIDS-related deaths
resulted m lower mortality ratios for 1986 to 1992, espe-
cially m patients with severe hemophiha After we ex-
cluded deaths caused by hver disease, the mortahty ratios
of patients with severe hemophiha (standardized mortality
ratio, l 2) resembled those of patients with mild disease
(standardized mortahty ratio, 10) The exclusion of
deaths related to AIDS and hver disease resulted m an
extrapolated overall life expectancy of 73 years, a value
equahng that of the general male population
Between 1986 and 1992, one patient died of heart
failure and no patients died of myocardial mfarction On
the basis of the mcidence of fatal ischemic heart disease
in Dutch men m 1989, 5 2 deaths from this cause were
expected, resultmg in a mortality ratio of 0 2 (CI, 0 0 to
11) The number of deaths from mahgnant neoplasms
Table 4. Standardized Mortality Ratios and Median Life Expectancies according to Severity of Hemophilia for the
Periods 1973 to 1986 and 1986 to 1992*
Variable Moderate Hemophiha Mild Hemophiha TotalSevere Hemophiha
Standardized Median Standardized Median Standardized Median Standardized Median
Mortality Life Mortahty Life Mortality Life Mortahty Life
Ratio Expectancy Ratio Expectancy Ratio Expectancy Ratio Expectancy
1973 to 1986
All (n = 717)t
1986 to 1992
All (n = 919)φ
Without AIDS
(n = 907)
Without AIDS or
hver disease
(n = 902)
29
40
19
12
63
61
69
73
23
26
23
21
65
65
66
67
16
11
10
10
69
74
74
74
21
20
15
12
66
68
70
73
* AIDS — acquired immunodeficiency syndrome Liver disease and AIDS were subsequently excluded from the analysis
t 7788 person years of follow up
t 5753 person years of follow up
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Table 5. Multivariate Survival Analyses for 1986 to 1992, Adjusted for Age*
Variable
Hemophiha Af
Hemophiha B
Severe hemophiha
Moderate hemophiha
Mild hemophihat
Inhibitor present
No mhibitor presentt
Receivmg prophylaxis
Not receivmg prophylaxist
HIV-positive
HlV-negativet
All
Number of
Patients
796
123
381
172
366
22
897
200
719
-
-
Patients (n = 919)
Relative Risk
(95% CI)
10
1 7 (0 9 to 3 4)
2 2 (1 0 to 5 0)
2 2 (1 0 to 4 9)
10
1 0 (0 1 to 7 5)
10
1 4 (0 6 to 3 2)
10
-
-
HIV-Tested
Number of
Patients
174
27
126
38
37
10
191
68
133
36
165
Patients (n = 201)
Relative Risk
(95% CI)
10
1 5 (0 3 to 7 6)
1 3 (0 2 to 9 0)
1 5 (0 2 to 11 6)
10
2 9 (0 3 to 31 9)
10
0 5 (0 1 to 2 6)
10
275(51 to 132 8)
10
* HIV = human immunodeficiency virus Age was divided mto 5 year categones, m dummy variables The model has separate results when HIV Status
is considered
t Reference category
(n = 7) was equal to the expected number (standardized
mortahty ratio, l 0 [CI, 04 to 2 1])
Risk Factors
Multivariate analysis (Table 5) confirmed a higher mor-
tahty with more severe forms of hemophiha The factor
most strongly related to the risk for death was HIV
mfection The multivanate model that accounted for HIV
Status, apphed to a subgroup of 201 patients who were
tested for and reported their HIV Status m 1985, showed
that seropositive patients (n = 36) had a 27 5-fold higher
risk than seronegative patients (n = 165) No other fac-
tors included in this model were significantly associated
with mortality After adjustment for HIV mfection, sever-
ity of hemophiha had httle effect because HIV mfection
was most prevalent m patients with severe hemophiha Of
the 36 patients who were seropositive for HIV, 29 had
severe hemophiha
Discussion
In the last decade, mortahty rates for patients with
hemophiha have dramatically worsened because of viral
infections Life expectancy would seem to have increased
m the absence of viral mfection An mcrease m virus-
related mortahty was most apparent among the severely
affected patients, who are the predommant users of clot-
tmg factor concentrates and are more likely to be mfected
with HIV or hepatitts than those with moderate or mild
hemophiha The observed mortahty rate among patients
with severe hemophiha between 1986 and 1992 was ap-
proximately four times higher than could be expected
from mortahty rates m the general male population
Patients with severe hemophiha were, on average,
younger than those with less severe forms This findmg
imphes that the mortahty ratlos, each standardized to the
patients' age distnbution, cannot be compared directly
within seventy categones (although each is m itself a fair
companson with the general male population) When
these age differences between patient groups were con-
sidered and HIV Status was not, äs m the proportional
hazards model (Table 5), the patients with severe hemo-
phiha had a 2 2-fold increased risk compared with pa-
tients who had mild hemophiha When HIV was consid-
ered, the patients with hemophiha had only a l 3-fold
increased risk Whereas overall mortahty remamed about
the same m 1986 to 1992 compared with 1973 to 1986, it
worsened among patients with HIV mfection, most of
these patients had severe hemophiha
We found a shghtly higher risk for death in patients
with hemophiha B than m those with hemophiha A, how-
ever, the CI was wide, and no significant difference was
seen (Table 5) In the previous penod (1973 to 1986), all
43 deaths had occurred m patients with hemophiha A
Therefore, over the total 20-year penod (1973 to 1992),
mortality m both types of hemophiha was similar, this
findmg is consistent with the clmical notion that both
types run similar courses
Because the use of prophylaxis, seventy of hemophiha,
mhibitor Status, and HIV Status are all related, relative
risk can only be properly analyzed m a multivanate
model Such a model for 1986 to 1992 (Table 5) sug-
gested that no hemophiha-related factors were mdepen-
dently associated with the risk for death We could not
estabhsh the relative risk induced by co-mfection with
hepatitis C virus because we had no Information on the
hepatitis C virus Status
Patients who received prophylaxis appeared to have a
risk for death that was only half that of patients who did
not receive prophylaxis, although the CI was wide Be-
tween 1973 and 1986 (11), mortahty was lower m patients
receivmg prophylaxis, but the difference was less pro-
nounced Chance is unhkely to explam these repeated
observations The effect may have been caused, however,
by other differences between patients who received and
did not receive prophylaxis that may be related to the risk
for death Prophylactic treatment, that is, mdintammg a
greater clottmg activity (clottmg factor level, > 0 01 IU/
mL), may indeed reduce mortality by dimmishing the
frequency or senousness of bleedmg
Compared with 1973 to 1986, the effect of Inhibitors on
mortality decreased, this factor no longer contnbuted sig-
nificantly to the risk for death The crude mortahty (that
is, not adjusted for HIV Status) for the patients followed
from 1986 to 1992 who had an mhibitor was exactly the
same äs m the patients who did not have Inhibitors (Table
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5). After adjustment for HIV Status, the relative nsk was
increased (relative risk, 2.9 [CI, 0.3 to 31.9]). The risk was
more pronounced between 1973 and 1986 (relative risk,
5.3 [CI, 1.9 to 11.5]), when 7 of 30 patients with an
inhibitor died (11), compared with l of 22 patients with
an inhibitor between 1986 and 1992.
Although ischemic heart disease is a common cause of
death in the general Dutch male population (causmg ap-
proximately 19% of all deaths in 1991), it accounted for
only 2% of all deaths among patients with hemophilia
between 1986 and 1992. On the basis of the 1973 to 1986
follow-up, we concluded that hemophilia might offer pro-
tection against ischemic heart disease (11, 15), a conclu-
sion that is substantiated by the results for the cohort
followed from 1986 to 1992. Over the total 20-year pe-
nod, 2 patients died of ischemic heart disease compared
with the 10.2 who were expected to die of that condition;
the resulting overall mortality ratio was 0.2 (CI, 0.0 to
0.7). Other researchers have suggested that a high level of
factor VIII activity is associated with an increased inci-
dence of ischemic heart disease because it predisposes
patients to thrombosis (16); the opposite appears to be
true with hemophilia.
Although the results of the previous follow-up study
(11) showed an excess mortality from cancer (standard-
ized mortality ratio, 2.5 [CI, 1.4 to 4.2]), we found no
excess mortality from cancer in the cohort followed from
1986 to 1992 (standardized mortality ratio, 1.0).
Deaths from AIDS and hver disease markedly in-
creased mortality rates, and, although this effect is ex-
pected to be temporary, the devastatmg consequences for
survival will last äs long äs patients with hemophilia are
infected with HIV or hepatitis virus. Although many pa-
tients survive for many years after being mfected with
HIV without developing AIDS (17), the prognosis for
most patients with HIV mfection remains bleak. Current
estimates predict that at least 50% of patients mfected
with hepatitis C will develop chronic hepatitis and that
many of them will progress to liver cirrhosis (18). In
addition, the development of liver disease is accelerated
by HIV mfection (19, 20). Because most patients with
hemophilia have become infected with hepatitis viruses or
HIV, or both, we will see the consequences of this for
many years to come unless effective therapies are devel-
oped. Although we can conclude from our studies that
hfe expectancy in patients with hemophilia will be almost
normal in the absence of viral infections, decades may
pass before mortality is no longer excessive compared
with that of the general male population.
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